Catecholaminergic polymorphic ventricular tachycardia implantable cardioverter-defibrillator: Difference between revisions
No edit summary |
|||
| Line 5: | Line 5: | ||
==Overview== | ==Overview== | ||
[[Implantable cardioverter defibrillator]] should be used with pharmacologic therapy. It is recommended in patients who are at high risk of [[cardiac arrest]], patients who have survived a [[sudden cardiac arrest]] and patients who have experienced [[syncope]] or sustained [[VT]] despite optimal medical therapy. | |||
==Implantable Cardioverter-Defibrillator== | ==Implantable Cardioverter-Defibrillator== | ||
Revision as of 14:48, 23 July 2020
|
Catecholaminergic polymorphic ventricular tachycardia Microchapters |
|
Differentiating Catecholaminergic polymorphic ventricular tachycardia from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Catecholaminergic polymorphic ventricular tachycardia implantable cardioverter-defibrillator On the Web |
|
American Roentgen Ray Society Images of Catecholaminergic polymorphic ventricular tachycardia implantable cardioverter-defibrillator |
|
FDA on Catecholaminergic polymorphic ventricular tachycardia implantable cardioverter-defibrillator |
|
CDC on Catecholaminergic polymorphic ventricular tachycardia implantable cardioverter-defibrillator |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mounika Reddy Vadiyala, M.B.B.S.[2]
Overview
Implantable cardioverter defibrillator should be used with pharmacologic therapy. It is recommended in patients who are at high risk of cardiac arrest, patients who have survived a sudden cardiac arrest and patients who have experienced syncope or sustained VT despite optimal medical therapy.
Implantable Cardioverter-Defibrillator
- Implantable cardioverter defibrillator should be used with pharmacologic therapy.[1]
- Indications:[2]
- Patients who are at high risk of cardiac arrest
- Patients who have survived a sudden cardiac arrest
- Patients who have experienced syncope or sustained VT despite optimal medical therapy and left cardiac sympathetic denervation. [].
- Implantable cardioverter-defibrillator may have harmful pro-arrhythmic effects in some patients, since painful shocks can increase catecholamine release and trigger further arrhythmias and triggering VT storm, leading to a malignant cycle of shocks that may even culminate in death.
- To reduce the risk of inappropriate shocks, it is important to program ICD with long delays before shock delivery and high cut-off rates for heart rate recognition; and always administer beta blockers concurrently.[3]
References
- ↑ Roston, Thomas M.; Jones, Karolina; Hawkins, Nathaniel M.; Bos, J. Martijn; Schwartz, Peter J.; Perry, Frances; Ackerman, Michael J.; Laksman, Zachary W.M.; Kaul, Padma; Lieve, Krystien V.V.; Atallah, Joseph; Krahn, Andrew D.; Sanatani, Shubhayan (2018). "Implantable cardioverter-defibrillator use in catecholaminergic polymorphic ventricular tachycardia: A systematic review". Heart Rhythm. 15 (12): 1791–1799. doi:10.1016/j.hrthm.2018.06.046. ISSN 1547-5271.
- ↑ Priori, Silvia G.; Blomström-Lundqvist, Carina; Mazzanti, Andrea; Blom, Nico; Borggrefe, Martin; Camm, John; Elliott, Perry Mark; Fitzsimons, Donna; Hatala, Robert; Hindricks, Gerhard; Kirchhof, Paulus; Kjeldsen, Keld; Kuck, Karl-Heinz; Hernandez-Madrid, Antonio; Nikolaou, Nikolaos; Norekvål, Tone M.; Spaulding, Christian; Van Veldhuisen, Dirk J. (2015). "2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death". European Heart Journal. 36 (41): 2793–2867. doi:10.1093/eurheartj/ehv316. ISSN 0195-668X.
- ↑ Al-Khatib, Sana M.; Stevenson, William G.; Ackerman, Michael J.; Bryant, William J.; Callans, David J.; Curtis, Anne B.; Deal, Barbara J.; Dickfeld, Timm; Field, Michael E.; Fonarow, Gregg C.; Gillis, Anne M.; Granger, Christopher B.; Hammill, Stephen C.; Hlatky, Mark A.; Joglar, José A.; Kay, G. Neal; Matlock, Daniel D.; Myerburg, Robert J.; Page, Richard L. (2018). "2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death". Journal of the American College of Cardiology. 72 (14): e91–e220. doi:10.1016/j.jacc.2017.10.054. ISSN 0735-1097.